These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Quality by design approach for understanding the critical quality attributes of cyclosporine ophthalmic emulsion. Rahman Z; Xu X; Katragadda U; Krishnaiah YS; Yu L; Khan MA Mol Pharm; 2014 Mar; 11(3):787-99. PubMed ID: 24423028 [TBL] [Abstract][Full Text] [Related]
6. Comment on "Quality by design approach for understanding the critical quality attributes of cyclosporine ophthalmic emulsion". Gore A; Attar M; Pujara C; Neervannan S Mol Pharm; 2014 Jul; 11(7):2490-2. PubMed ID: 24803420 [No Abstract] [Full Text] [Related]
7. Stability of an ophthalmic micellar formulation of cyclosporine A in unopened multidose eyedroppers and in simulated use conditions. Chennell P; Delaborde L; Wasiak M; Jouannet M; Feschet-Chassot E; Chiambaretta F; Sautou V Eur J Pharm Sci; 2017 Mar; 100():230-237. PubMed ID: 28131754 [TBL] [Abstract][Full Text] [Related]
8. Osmolarity of prevalent eye drops, side effects, and therapeutic approaches. Dutescu RM; Panfil C; Schrage N Cornea; 2015 May; 34(5):560-6. PubMed ID: 25789693 [TBL] [Abstract][Full Text] [Related]
9. [Development of new magistral method for the preparation of artificial tears]. Kovács G; Varga D; Sebe I; Hajdú M; Szabó P; Ostorházi E; Antal I Acta Pharm Hung; 2015; 85(4):139-43. PubMed ID: 26964402 [TBL] [Abstract][Full Text] [Related]
10. In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease. Rodriguez-Aller M; Kaufmann B; Guillarme D; Stella C; Furrer P; Rudaz S; El Zaoui I; Valamanesh F; Di Tommaso C; Behar-Cohen F; Veuthey JL; Gurny R Eur J Pharm Biopharm; 2012 Apr; 80(3):544-52. PubMed ID: 22155591 [TBL] [Abstract][Full Text] [Related]
11. Comparison of 1% cyclosporine eye drops in olive oil and in linseed oil to treat experimentally-induced keratoconjunctivitis sicca in rabbits. Parrilha LR; Nai GA; Giuffrida R; Barbero RC; Padovani LD; Pereira RH; Silva DA; Silva MC; Diniz MS; Andrade SF Arq Bras Oftalmol; 2015; 78(5):295-9. PubMed ID: 26466228 [TBL] [Abstract][Full Text] [Related]
12. [Compounding of ophthalmic drugs in the pharmacy. Special care must be taken!]. Daniels R Pharm Unserer Zeit; 2010 Jul; 39(4):306-11. PubMed ID: 20589805 [No Abstract] [Full Text] [Related]
13. Development of a cyclodextrin-based aqueous cyclosporin A eye drop formulations. Jóhannsdóttir S; Jansook P; Stefánsson E; Loftsson T Int J Pharm; 2015 Sep; 493(1-2):86-95. PubMed ID: 26220650 [TBL] [Abstract][Full Text] [Related]
14. Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts. Lallemand F; Schmitt M; Bourges JL; Gurny R; Benita S; Garrigue JS Eur J Pharm Biopharm; 2017 Aug; 117():14-28. PubMed ID: 28315447 [TBL] [Abstract][Full Text] [Related]
15. Incorporation of drug particles for extended release of Cyclosporine A from poly-hydroxyethyl methacrylate hydrogels. Kapoor Y; Dixon P; Sekar P; Chauhan A Eur J Pharm Biopharm; 2017 Nov; 120():73-79. PubMed ID: 28823714 [TBL] [Abstract][Full Text] [Related]
19. The Efficacy of Diquafosol Ophthalmic Solution in Non-Sjögren and Sjögren Syndrome Dry Eye Patients Unresponsive to Artificial Tear. Jeon HS; Hyon JY J Ocul Pharmacol Ther; 2016 Sep; 32(7):463-8. PubMed ID: 27294831 [TBL] [Abstract][Full Text] [Related]
20. Choice of artificial tear formulation for patients with dry eye: where do we start? Tong L; Petznick A; Lee S; Tan J Cornea; 2012 Nov; 31 Suppl 1():S32-6. PubMed ID: 23038032 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]